Completed
Effect of Rifampin (RIF) on the Pharmacokinetics (PK) of Oral Cabotegravir (CAB) in Healthy Subjects
NCT02411435
- Conditions
- Acquired Immunodeficiency Syndrome, Blood-Borne Infections, Communicable Diseases, +14 more
- Locations
-
- GSK Investigational Site Overland Park, Kansas, United States